Biotechnology company Akari Therapeutics, Plc (AKTX) announced Wednesday leadership changes, including the appointment of experienced life sciences entrepreneur Samir Patel as interim Chief Executive Officer.Rachelle Jacques will step down as Akari's CEO effective today. Melissa Bradford-Klug will step down as Akari's Chief Operating Officer effective today.

生物技术公司Akari Therapeutics，Plc（AKTX）周三宣布领导层变动，包括任命经验丰富的生命科学企业家萨米尔·帕特尔为临时首席执行官。瑞秋·雅克（RachelleJacques）将辞去Akari首席执行官一职，从今天起生效。梅丽莎·布拉德福德·克鲁格（MelissaBradfordKlug）将辞去阿卡里（Akari）首席运营官一职，从今天起生效。

In connection with Jacques' departure, Akari's board of directors has appointed Patel as Interim CEO. Patel has served as a member of the Board since December 2023.Patel is a long-time supporter and investor in Akari and brings in broad life sciences experience and a track record of multiple successful startup companies..

关于雅克的离职，阿卡里董事会任命帕特尔为临时首席执行官。Patel自2023年12月起担任董事会成员。Patel是Akari的长期支持者和投资者，拥有丰富的生命科学经验和多家成功创业公司的业绩记录。。

Patel currently serves as founder and principal of PranaBio Investments, LLC. He is also a consultant to GE Global Research, GE's innovation engine that is creating novel products and solutions across several sectors including biomanufacturing and biotechnology.He has more than 20 years of experience in life sciences including co-founding Digital Therapeutics, LLC, and SPEC Pharma, LLC.

Patel目前担任PranaBio Investments，LLC的创始人和负责人。他还是GE Global Research的顾问，GE是GE的创新引擎，致力于在生物制造和生物技术等多个领域创造新产品和解决方案。他在生命科学领域拥有20多年的经验，包括共同创立数字治疗有限责任公司和SPEC Pharma有限责任公司。

Previously, Patel held multiple roles in Medical Affairs with Centocor, Inc. For comments and feedback contact: editorial@rttnews.comBusiness News.

此前，Patel曾在Centocor，Inc.的医疗事务中担任多个角色，以征求意见和反馈联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股